Abstract
This chapter provides an overview of the genetic and proteomic high-throughput platforms and the statistical methods used to evaluate molecular biomarkers for cancer diagnosis. Commonly, these experimental platforms are used in cancer diagnosis where the biomarkers can be used to determine cancer subtypes and thus potential treatments. Because of the large amount of data from these platforms, accurate testing methods are necessary. In this chapter, we highlight the statistical methods used to evaluate each potential biomarker and limit the number of false positives under a specific error rate.
| Original language | English |
|---|---|
| Title of host publication | Statistical Diagnostics for Cancer |
| Subtitle of host publication | Analyzing High-Dimensional Data |
| Publisher | Wiley-VCH |
| Pages | 1-26 |
| Number of pages | 26 |
| Volume | 3 |
| ISBN (Print) | 9783527332625 |
| DOIs | |
| State | Published - Apr 8 2013 |
Keywords
- Complementary DNA (cDNA)
- DNA methylation
- False discovery rate (FDR)
- Messenger RNA (mRNA)
- Partial deviance (PD)
- Proteomic high-throughput platforms
Fingerprint
Dive into the research topics of 'Control of Type I Error Rates for Oncology Biomarker Discovery with High-Throughput Platforms'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver